Chk2 Inhibitor

A cell-permeable, ATP competitive, and reversible indoloazepine compound that displays anti-proliferative and anti-inflammatory properties. Acts as a potent inhibitor of Chk2 (IC₅₀ = 8 nM) that targets the ATP binding pocket. Exhibits selectivity for Chk2 over MEK1, Chk1, CK1δ, PKCα, PKCβII and CK2 (IC₅₀ = 89 nM, 237 nM, 1.352 µM, 2.539 µM, 3.381 µM, and >10.0 µM, respectively). Blocks the production of IL-2 and TNF-α by preventing the transcriptional activation of NF-κB (IC₅₀ = 3.55 µM for IL-2 production in PMA-stimulated Jurkat T cells; 8.16 µM for TNF-α production in LPS-stimulated THP-1 cells). Also reported to suppress the growth of leukemic T cells (GI₅₀ = 1.73 µM).

Primary Target
Chk2

Target IC₅₀: 8 nM against Chk2

Toxicity: Carcinogenic / Teratogenic (D)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Sharma, V., and Tepe, J.J. 2004. Bioorg. Med. Chem. Lett.14, 4319.
Sharma, V., et al. 2004. J. Med. Chem.47, 3700.

Sold under license from Michigan State University.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany